Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Prime Medicine (PRME) stays a Buy as PM577/PM647 advance in vivo prime editing for Wilson’s & AATD; key INDs 2H 2026, data ...